Table 3.

Changes in the ARR, EDSS, VFSS, and length of spinal cord lesions before and after treatment with low-dose RTX in the overall sample.

n = 36	ARR	EDSS	VFSS	Length of spinal cord lesions
Before RTX treatment	1.97 ± 1.93	3.43 ± 1.49	1.50 ± 1.76	5.54 ± 3.96
After RTX treatment	0.12 ± 0.32	3.10 ± 1.88	1.43 ± 1.73	4.31 ± 3.73
Significance level	0.000	0.013	0.169	0.001*

^*Data from 35 cases were analyzed, 1 patient died, and no recent MRI was available.

ARR, annualized relapse rate; EDSS, expanded disability status scale; VFSS, visual function system scale; RTX, rituximab.